US00847G8042 - Common Stock
AGEN earnings call for the period ending March 31, 2024.
AGEN stock results show that Agenus missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
This small-cap biotech stock is surging. Time to buy?
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.
These stocks could rocket higher, but they also present significant risks.
If you want the chance at possible absurd returns, then consider gambling on these stocks to turn $1,000 into $1 million.
AGEN earnings call for the period ending December 31, 2023.
The company hopes to engineer a 1-for-20 reverse stock split.
SaponiQx, a unit of Agenus (AGEN), and Ginkgo Bioworks (DNA) have won a multi-year contract worth up to $31M to sudy vaccine adjuvants. Read more here.
/PRNewswire/ -- The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program...
TD Cowen argues that Moderna's (MRNA) upcoming mRNA-based RSV vaccine has a faster decline in efficacy compared to rival shots from Pfizer (PFE) and GSK (GSK). Read more here.
GSK's respiratory syncytial virus (RSV) vaccine, Arexvy, is under priority review by the FDA for a label expansion to age group 50-59. Read more here.